Evaluation of Phoxilium® to Prevent HypoPHOSPHATEmia compared to Hemosol B0® or Prismocol B22 during Citrate-based Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU)

Austin Health0 个研究点目标入组 30 人开始时间: 2023年11月8日最近更新: 2024年5月21日

适应症

试验速览

暂无简介。

•Patients will be included from the study if ALL the following criteria are present:
•Have severe acute kidney injury.
•Continuous renal replacement therapy is to commence.
•Will receive regional citrate anticoagulation as a component of CRRT.
•Expected to receive CRRT for equal to or greater than 48 hours.
•The treating clinician believe that using Phoxilium® or Hemosol B0 are equally indicated and appropriate.

•Patients will be EXCLUDED from the study if ONE of the following criteria presents:
•Age is less than 18 years of age.
•Not For Resuscitation (NFR) order in place during the index intensive care unit admission
•Death is deemed imminent or inevitable during this admission, and either the attending physician, patient or substitute decision-maker is not committed to active treatment.
•Patients with known HIV infection
•Any other illness that, in the investigator’s judgement, will substantially increase the risk associated with subject’s participation in this study.
•Patient needs to receive systemic anticoagulation for other indications.

发起方